Replies to post #2160 on BioCurex, Inc.(fka BOCX)

[Kag]

The no volume yesterday was an event of no significance. The stock had a slightly larger than usual volume the day before, and I will predict a normal or slightly larger than normal volume for today. For investors, this stock is in the typical biotech waiting mode. Waiting always tests the patience of investors. When the waiting has gone on for almost a year, as it has with BOCX, the price invariably drifts lower. When everything known to investors indicates that the fundamentals have not changed, it presents a opportunity to buy stock a low price. But it is not easy to keep focusing on what is important. If an investor liked the stock after the Abbott licensing announcement, an investor should really like the stock now, at the lower price, especially when a big chunk of the waiting for additional news has already occurred. It should also be emphasized that Abbott would have done some preliminary testing on the RECAF technology before they plunked down their up front money. Abbott has also had ample time since the licensing occurred, in March 2005, to return the technology if it did not work as expected. Combine that with Moro writing to Steelcitydog, in response to his recent email, to "keep an eye on the company." That was recent, definite encouragement by the CEO. Keep in mind that Moro surely knows that there are permanent records of emails, and I am guessing that there was no disclaimer attached to the email. Based on what is known at the present time, BOCX investors should be pretty happy this morning. "The company is in good shape and there is a natural progression from where we were when we licensed the technology to Abbott." Kag